Spero Therapeutics, Inc.
SPRODrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SPRO Earnings Report
FQ end 2026-06
How SPRO's past catalysts played out
TBP-PI-HBr
Urinary Tract Infection
TBPM-PI-HBr
Complicated Urinary Tract Infection
SPR720 500 mg
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TBP-PI-HBr | Phase 3 | Urinary Tract Infection | - | - |
TBPM-PI-HBr | Phase 3 | Complicated Urinary Tract Infection | - | - |
SPR720 500 mg | Phase 2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Spero Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Spero Therapeutics, Inc.'s (SPRO) pipeline across Phase 3, Phase 2. Its lead program is TBP-PI-HBr (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Spero Therapeutics, Inc.'s next FDA catalyst?→
Spero Therapeutics, Inc.'s (SPRO) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SPRO biotech catalysts?→
Add SPRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Spero Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.